ArticleCancers2023

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission.

Beryl L Manning-Geist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.